[1]孟建华.参芪扶正注射液联合三参芪口服液对宫颈癌术后放疗患者细胞免疫功能的影响[J].现代中西医结合杂志,2017,26(05):477-480. [2] 包鹤龄.中国2006-2012年子宫颈癌死亡情况与变化趋势分析[J].中华流行病学杂志,2017,38(1):58-64. [3] Prat J. FIGO staging for uterine sarcoma[J].Int Gynaecol Obstet,2009,105(2):103-104. [4] 朱雨,郭瑞霞,李留霞,等.宫颈锥切术后病理由CINⅢ升级为宫颈癌的相关预测因素分析[J].现代妇产科进展,2017,26(01):49-51. [5] 谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2014. [6] 万崇华,陈明清,张灿珍,等.癌症患者生命质量测定量表EORTC+QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(04):353-356. [7] 杨军凤,李辉.外科手术联合介入治疗宫颈癌ⅡB期患者的回顾性研究[J].检验医学与临床,2017,14(1):142-143. [8] Yamamoto T, Yoshimatsu H, Yamamoto N, et al.Multisite lymphaticovenular anastomosis using vein graft for uterine cancer-related lymphedema after pelvic lymphadenectomy[J].Vasc Endovascular Surg,2015,49(7):195-200. [9] 孔德强,李春静,盛修贵.前哨淋巴结检测结果指导肿瘤＞2cm的Ⅰ b1期宫颈癌行广泛性宫颈切除术的临床研究[J].肿瘤学杂志,2016,22(12):998-1003. [10] 孟祥凯,郭毅,唐艳君,等.治疗方案对宫颈癌患者生存质量影响的分析[J].中国妇幼保健,2016,31(12):2432-2434. [11] Schwartz L, Schrot-Sanyan S, Brigand C,et al.Impact of pelvic and para-aortic lymphadenectomy in advanced ovarian cancer after neoadjuvant chemotherapy[J].Anticancer Res,2015,35(10):5503-5509. [12] 黄吕成,翟建波.腹腔镜下保留盆腔自主神经功能广泛子宫切除对排尿功能及性生活质量的影响[J].中国性科学,2016,25(10):29-32. [13] Ruengkhachorn I, Therasakvichya S, Warnnissorn M,et al.Pathologic risk factors and oncologic outcomes in early-stage cervical cancer patients treated by radical hysterectomy and pelvic lymphadenectomy at a thai university hospital: a 7 year retrospective review[J].Asian Pac J Cancer Prev,2015,16(14):5951-5956. [14] 李莉,杨晓清.腹腔镜下宫颈癌保留神经平面广泛子宫切除术的临床效果[J].中国计划生育学杂志,2016,24(8):548-551.
2017, Vol. 34 
